Xieli Pharmaceutical Invested in SSCIP

On the afternoon of December 24, Sichuan Xieli Pharmaceutical Co., Ltd. (Xieli Pharmaceutical), the only pharmaceutical company in Sichuan whose raw materials and final products are both certified by GMP, won the bid for an industrial land in SSCIP, marking its successful entry in SSCIP. Xieli Pharmaceutical plans to invest RMB 500 million for the construction of its R&D center and headquarters in SSCIP.

Biomedical sciences industry has long been the main focus of SSCIP. Using Singapore’s Biopolis as a model, SSCIP endeavors to build 4 critical platforms by securing catalytic projects, and integrating local resources to form an international biomedical ecosystem. So far, SSCIP has secured in 5 bio-medicine projects, including Chipscreen, Good doctor, Haisco, Chengdu Jetta and Xieli Pharmaceutical. The settlement of Xieli will further facilitate the establishment of critical platforms for the biomedical sciences industry.

Location: the fourth cluster in SSCIP mainly planned for the development of biomedical sciences industry.

About Sichuan Xieli Pharmaceutical Co., Ltd. (Xieli Pharmaceutical)

Founded in 1992, Xieli Pharmaceutical is one of world-leading suppliers of flavonoids, anti-malaria drugs, cytotoxic antitumor drugs. It is a leading GMP manufacturer of drugs based on plants and animals. Xieli Pharmaceutical owns 3 production bases and 3 herb-planting bases with the ability to produce over 40 kinds of extracts and APIs, and holds more than 80 pharmaceutical certificates. The company has developed partnerships with more than a dozen of Fortune Global 500 pharmaceutical companies, covering wide areas such as product sales, R&D, contract production, and technology transfer.